Companies › Biossil
1 active drug program in 3 registered trials: 3 Phase 2; Neurology, Hematology, Respiratory; next expected readout Oct 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Senicapoc (SIL-8301) Intermediate conductance calcium-activated potassium channel protein 4 blocker | Ion channels | Phase 2 | Sickle Cell Disease; Mild Cognitive Impairment; Pulmonary Fibrosis, Interstitial Lung Disease | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04804241 | Senicapoc (SIL-8301) | Phase 2 | Mild Cognitive Impairment | Neurology | Dec 2027 |
| NCT06714123 | Senicapoc (SIL-8301) | Phase 2 | Pulmonary Fibrosis, Interstitial Lung Disease | Respiratory | Dec 2028 |
| NCT07282210 | Senicapoc (SIL-8301) | Phase 2 | Sickle Cell Disease | Hematology | Oct 2029 |
Actio Biosciences Halia Therapeutics Nuvig Therapeutics Aspeya Shenzhen Ausa Pharmed
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.